AU2009314266A1 - Biodegradable alpha-2 adrenergic agonist polymeric implants - Google Patents

Biodegradable alpha-2 adrenergic agonist polymeric implants Download PDF

Info

Publication number
AU2009314266A1
AU2009314266A1 AU2009314266A AU2009314266A AU2009314266A1 AU 2009314266 A1 AU2009314266 A1 AU 2009314266A1 AU 2009314266 A AU2009314266 A AU 2009314266A AU 2009314266 A AU2009314266 A AU 2009314266A AU 2009314266 A1 AU2009314266 A1 AU 2009314266A1
Authority
AU
Australia
Prior art keywords
implant
polymer
lactide
alpha
brimonidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009314266A
Other languages
English (en)
Inventor
Alazar N. Ghebremeskel
Michael R. Robinson
Lon T. Spada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AU2009314266A1 publication Critical patent/AU2009314266A1/en
Priority to AU2016204582A priority Critical patent/AU2016204582A1/en
Priority to AU2018202557A priority patent/AU2018202557B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
AU2009314266A 2008-11-17 2009-11-06 Biodegradable alpha-2 adrenergic agonist polymeric implants Abandoned AU2009314266A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2016204582A AU2016204582A1 (en) 2008-11-17 2016-07-01 Biodegradable alpha-2 adrenergic agonist polymeric implants
AU2018202557A AU2018202557B2 (en) 2008-11-17 2018-04-12 Biodegradable alpha-2 adrenergic agonist polymeric implants

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/272,548 2008-11-17
US12/272,548 US9095506B2 (en) 2008-11-17 2008-11-17 Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
PCT/US2009/063490 WO2010056598A2 (en) 2008-11-17 2009-11-06 Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016204582A Division AU2016204582A1 (en) 2008-11-17 2016-07-01 Biodegradable alpha-2 adrenergic agonist polymeric implants

Publications (1)

Publication Number Publication Date
AU2009314266A1 true AU2009314266A1 (en) 2010-05-20

Family

ID=41698087

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2009314266A Abandoned AU2009314266A1 (en) 2008-11-17 2009-11-06 Biodegradable alpha-2 adrenergic agonist polymeric implants
AU2016204582A Abandoned AU2016204582A1 (en) 2008-11-17 2016-07-01 Biodegradable alpha-2 adrenergic agonist polymeric implants
AU2018202557A Ceased AU2018202557B2 (en) 2008-11-17 2018-04-12 Biodegradable alpha-2 adrenergic agonist polymeric implants

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2016204582A Abandoned AU2016204582A1 (en) 2008-11-17 2016-07-01 Biodegradable alpha-2 adrenergic agonist polymeric implants
AU2018202557A Ceased AU2018202557B2 (en) 2008-11-17 2018-04-12 Biodegradable alpha-2 adrenergic agonist polymeric implants

Country Status (7)

Country Link
US (7) US9095506B2 (https=)
EP (1) EP2355795B1 (https=)
JP (2) JP5580832B2 (https=)
AU (3) AU2009314266A1 (https=)
CA (1) CA2743837C (https=)
ES (1) ES2624448T3 (https=)
WO (1) WO2010056598A2 (https=)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
CA3186189A1 (en) 2009-05-18 2010-11-25 Dose Medical Corporation Drug eluting ocular implant
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP2437684B1 (en) 2009-06-03 2022-06-15 ForSight Vision5, Inc. Anterior segment drug delivery
PH12012500928A1 (en) 2009-11-09 2012-11-26 Allergan Inc Compositions and methods for stimulating hair growth
EP3085358B1 (en) 2010-01-22 2017-11-01 Allergan, Inc. Intracameral sustained release therapeutic agent implants
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
WO2012112638A1 (en) * 2011-02-18 2012-08-23 Valeant International (Barbados) Srl Cross reference to related applications
US20120276186A1 (en) 2011-04-29 2012-11-01 Ghebremeskel Alazar N Sustained release latanoprost implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
EP2755615B1 (en) 2011-09-14 2022-04-06 Forsight Vision5, Inc. Ocular insert apparatus
JP6138904B2 (ja) 2012-03-16 2017-05-31 ザ・ジョンズ・ホプキンス・ユニバーシティー 活性剤の送達のための非線状マルチブロックコポリマー薬物コンジュゲート
US8962577B2 (en) 2012-03-16 2015-02-24 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
DK2911623T3 (da) 2012-10-26 2019-10-28 Forsight Vision5 Inc Oftalmisk system til langvarig frigivelse af lægemiddel til øjet
CN109602691A (zh) * 2013-02-15 2019-04-12 阿勒根公司 持续药物递送植入物
JP2016520561A (ja) 2013-04-12 2016-07-14 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 脂肪減少のためのビマトプロスト、ビマトプロスト類似体、プロスタミド及びプロスタグランジンの持続放出
CN105682645B (zh) 2013-10-31 2019-09-06 阿勒根公司 含前列腺酰胺的眼内植入物及其使用方法
MX2016007345A (es) * 2013-12-06 2016-12-09 Envisia Therapeutics Inc Implante intracameral para el tratamiento de una condicion ocular.
AU2015264181A1 (en) * 2014-05-23 2016-12-01 Ocular Technologies Sarl Topical formulations and uses thereof
EP3677229A1 (en) 2014-05-29 2020-07-08 Glaukos Corporation Implants with controlled drug delivery features
PL3179982T3 (pl) 2014-07-28 2023-09-25 Sun Pharma Advanced Research Company Ltd Sposób zwiększenia biodostępności i/lub przedłużenia działania oftalmicznego leku
MX2017001863A (es) 2014-08-13 2017-07-17 Univ Johns Hopkins Nanoparticulas cargadas con glucocorticoides para prevencion de rechazo de aloinjerto corneal y neovascularizacion.
CN107278151A (zh) 2014-12-15 2017-10-20 约翰霍普金斯大学 舒尼替尼制剂及其在治疗青光眼中的使用方法
WO2016118506A1 (en) 2015-01-20 2016-07-28 The Johns Hopkins University Compositions for the sustained release of anti-glaucoma agents to control intraocular pressure
HK1249460A1 (zh) 2015-03-06 2018-11-02 Aerie Pharmaceuticals, Inc. 植入物施用器和植入物的施用方法
WO2016149194A1 (en) 2015-03-13 2016-09-22 MAM Holdings of West Florida, L.L.C. Collagen compositions and uses for biomaterial implants
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
EP3324944A4 (en) 2015-07-23 2019-04-03 Aerie Pharmaceuticals, Inc. INTRAVITREAL AGGREGATION SYSTEMS FOR THE TREATMENT OF EYE DISEASE
JP6856620B2 (ja) * 2015-07-27 2021-04-07 サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッドＳｕｎ Ｐｈａｒｍａ Ａｄｖａｎｃｅｄ Ｒｅｓｅａｒｃｈ Ｃｏｍｐａｎｙ Ｌｉｍｉｔｅｄ 薬剤搭載ナノ樹脂粒子
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
CN108367079B (zh) 2015-11-12 2022-11-22 灰色视觉公司 用于治疗的聚集性微粒
US9579350B1 (en) 2016-02-25 2017-02-28 MAM Holdings of West Florida, L.L.C. Human amniotic fluid preparation having long-term stability
WO2017151879A1 (en) 2016-03-02 2017-09-08 The Johns Hopkins University Compositions for sustained release of anti-glaucoma agents to control intraocular pressure
EP3442479B1 (en) 2016-04-20 2026-03-04 Glaukos Corporation Bioresorbable ocular drug delivery device
JP2019534063A (ja) 2016-09-02 2019-11-28 エンビシャ セラピューティクス インコーポレイテッド インプラントアプリケータ
CA3056923A1 (en) 2017-03-23 2018-09-27 Graybug Vision, Inc. Drugs and compositions for the treatment of ocular disorders
US11160870B2 (en) 2017-05-10 2021-11-02 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
WO2019071245A1 (en) 2017-10-06 2019-04-11 Foundry Therapeutics, Inc. IMPLANTABLE DEPOSITS FOR REGULATED RELEASE OF ANALGESICS TO TREAT POSTHOPERATIVE PAIN ASSOCIATED WITH ORTHOPEDIC SURGERY, AND RELATED DEVICES, SYSTEMS, AND METHODS
WO2019136490A1 (en) 2018-01-08 2019-07-11 Foundry Therapeutics, Inc. Devices, systems, and methods for treating intraluminal cancer via controlled delivery of therapeutic agents
EP3793536A1 (en) 2018-05-12 2021-03-24 Foundry Therapeutics, Inc. Implantable polymer depots for the controlled release of therapeutic agents
MX2020014160A (es) * 2018-06-25 2021-03-09 Titan Pharmaceuticals Inc Implantes para liberacion de sustancias farmaceuticas lipofilicas o anfifilicas.
US12303619B2 (en) 2018-08-28 2025-05-20 Foundry Therapeutics, Inc. Polymer implants
MX2021010599A (es) * 2019-03-05 2021-12-10 Aerie Pharmaceuticals Inc Composiciones farmaceuticas para el tratamiento de enfermedades o trastornos oculares.
BR112023001073A2 (pt) 2020-07-21 2023-03-07 Allergan Inc Implante intraocular com alto carregamento de prostamida
AU2023355823A1 (en) 2022-10-05 2025-04-17 Mireca Medicines Gmbh MICROPARTICLE AND IMPLANT FORMULATIONS FOR cGMP ANALOG THERAPY
WO2025179071A1 (en) * 2024-02-20 2025-08-28 Bausch + Lomb Ireland Limited Sustained-release drug delivery compositions for treating ocular diseases

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2054102A (en) 1936-09-15 Voting machine
NL64744C (https=) 1940-03-09
US2401708A (en) 1943-01-19 1946-06-04 Eastman Kodak Co Range finder
US2401408A (en) 1944-05-03 1946-06-04 Harold S Bixby Lock for fluorescent lamps
US2743837A (en) 1953-06-01 1956-05-01 Leon J Cook Lead sleeve expanding device
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
JPS58126435U (ja) 1982-02-19 1983-08-27 オリンパス光学工業株式会社 Ｔｔｌオ−トストロボ用絞り制御回路
US4521210A (en) 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
US5264188A (en) 1991-01-22 1993-11-23 Phillips Petroleum Company Multi-stage hydrotreating process and apparatus
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6369116B1 (en) 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5856329A (en) 1995-06-28 1999-01-05 Allergan Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
AU4582797A (en) 1996-09-13 1998-04-02 Regents Of The University Of California, The Methods for treatment of retinal diseases
WO1999001156A1 (en) 1997-07-02 1999-01-14 Santen Pharmaceutical Co., Ltd. Polylactic acid scleral plugs
CA2300154C (en) 1997-08-11 2008-07-08 Allergan Sales, Inc. Sterile bioerodible implant device with improved biocompatability and method
PT1221918E (pt) 1999-10-21 2005-06-30 Alcon Inc Administracao de drogas sub-tenon
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US20010049369A1 (en) * 2000-02-10 2001-12-06 Jablonski Monica M. Brimonidine compositions and methods for retinal degeneration
US6692759B1 (en) 2000-06-28 2004-02-17 The Regents Of The University Of California Methods for preparing and using implantable substance delivery devices
AU2002248284A1 (en) 2000-11-01 2002-08-06 Allergan, Inc. Compositions for treatment of ocular neovascularization
AU2002236495B2 (en) 2000-11-29 2006-05-11 Allergan, Inc. Intraocular implants for preventing transplant rejection in the eye
NZ533434A (en) 2001-11-14 2006-11-30 Alza Corp Thixotropic gel composition for injectable deposition
DE60327693D1 (de) 2002-03-18 2009-07-02 Novartis Ag Topische zusammensetzung enthaltend ein cyclofructan, einen träger und einen arzneistoff
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
DE60318446T2 (de) 2002-07-15 2008-05-21 Alcon Inc. Nichtpolymere lipophile pharmazeutische implantat-zusammensetzungen für die intraokulare anwendung
US6899717B2 (en) 2002-09-18 2005-05-31 Allergan, Inc. Methods and apparatus for delivery of ocular implants
JP2006504741A (ja) * 2002-10-08 2006-02-09 アラーガン、インコーポレイテッド 痴呆およびパーキンソン病の処置における（２−イミダゾリン−２−イルアミノ）キノキサリンの使用方法
ATE418323T1 (de) 2002-11-06 2009-01-15 Alza Corp Depot-formulierungen mit verzögerter freisetzung
CA2513751C (en) 2003-01-24 2012-01-10 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of adrenergic agents
JP2005035235A (ja) * 2003-07-18 2005-02-10 Noritsu Koki Co Ltd 画像露光装置
US20050131372A1 (en) * 2003-12-10 2005-06-16 Kimberly-Clark Worldwide, Inc. Absorbent articles with removable protective wing portions
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US20050244471A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US20050244458A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US20060182781A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US7135391B2 (en) * 2004-05-21 2006-11-14 International Business Machines Corporation Polycrystalline SiGe junctions for advanced devices
US7931909B2 (en) * 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US11851905B2 (en) 2019-04-23 2023-12-26 Raily S.R.L. Modular railing suitable for variable installation slopes
US11902105B2 (en) 2022-05-24 2024-02-13 Red Hat, Inc. Interactive graphical user interface for visualizing flow data in a programmable network switch

Also Published As

Publication number Publication date
US9522113B2 (en) 2016-12-20
ES2624448T3 (es) 2017-07-14
US20200069578A1 (en) 2020-03-05
CA2743837C (en) 2017-03-28
US9861576B2 (en) 2018-01-09
CA2743837A1 (en) 2010-05-20
US20170100334A1 (en) 2017-04-13
AU2018202557A1 (en) 2018-05-10
US10842739B2 (en) 2020-11-24
JP2014184348A (ja) 2014-10-02
US9095506B2 (en) 2015-08-04
EP2355795A2 (en) 2011-08-17
US10471004B2 (en) 2019-11-12
JP2012509264A (ja) 2012-04-19
EP2355795B1 (en) 2017-01-04
JP5580832B2 (ja) 2014-08-27
AU2018202557B2 (en) 2020-02-27
US20180353426A1 (en) 2018-12-13
US20160030334A1 (en) 2016-02-04
AU2016204582A1 (en) 2016-07-21
US20230285279A1 (en) 2023-09-14
WO2010056598A3 (en) 2010-12-23
US20100124565A1 (en) 2010-05-20
WO2010056598A2 (en) 2010-05-20
US20210161809A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
US20230285279A1 (en) Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US9161938B2 (en) Sustained release intraocular implants and methods for treating ocular vasculopathies
US8293210B2 (en) Sustained release intraocular implants and methods for preventing retinal dysfunction
US8715709B2 (en) Sustained release intraocular implants and methods for treating ocular neuropathies
US20060233860A1 (en) Alpha-2 agonist polymeric drug delivery systems
HK1154496A (en) Methods of manufacturing intraocular implants of alpha-2 adrenergic receptor agonists

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted